Analysts expect Akari Therapeutics Plc to report revenue of 0.00 for Q2 25, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | - | 0.00 | 0.00 | - | - | - | - | - | |
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Akari Therapeutics Plc to report earnings per share of -23.32 for Q3 24, against a range of -24.64 to -22.00. The most recent reported quarter, Q2 26, came in at 0.00, a 100.0% beat against the -1.07 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | -6.80 | -5.40 | -2.40 | -4.00 | -2.99 | -9.74 | 0.00 | - | - | - | - | - | - | - | |||||||||||
| High Estimate | -22.00 | -38.89 | - | -3.18 | -1.56 | -1.60 | -1.23 | -1.02 | -1.86 | -0.90 | -0.99 | -1.10 | 0.74 | 4.16 | -2.86 | |||||||||||
| Low Estimate | -24.64 | -44.71 | - | -3.78 | -1.74 | -1.82 | -1.31 | -1.12 | -2.18 | -1.02 | -1.05 | -1.26 | 0.68 | 3.64 | -3.28 | |||||||||||
| Consensus Estimate | -23.32 | -41.80 | - | -3.48 | -1.65 | -1.71 | -1.27 | -1.07 | -2.02 | -0.96 | -1.02 | -1.18 | 0.71 | 3.90 | -3.07 |